Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females \> 18 years of age~* Active PsA with \> 3 tender and \> 3 swollen joints despite standard therapy~* Unsatisfactory response or intolerance to at least one prior or ongoing DMARD (study enrollment must be in accordance with current national guidelines for treatment of PsA with TNF inhibitors)~* A negative serum pregnancy test (serum HCG) for women of childbearing potential prior to the start of treatment.~* Use of a reliable method of contraception by all female patients of childbearing potential~* Able and willing to self-administer sc injections or have a suitable person to administer sc injections~* Able and willing to give written informed consent and comply with the protocol~Exclusion Criteria:~* Prior treatment with any investigational agent within 30 days or five half lives of the product, whichever is longer~* Treatment within last 2 months with infliximab or within last 3 weeks with etanercept~* Treatment within last 4 weeks with a combination of MTX and leflunomide~* Treatment within last 4 weeks with a combination of cyclosporine with any other DMARD-Subject has received UVA phototherapy (including PUVA within 2 weeks prior to screening)~* History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin or cervical dysplasia~* History of or current active acute inflammatory joint disease of origin other than PsA~* Comorbidities (uncontrolled diabetes, unstable ischemic heart disease, CHF, active IBD, stroke within 3 months, chronic leg ulcer and other condition which would put subject at risk by participation in the protocol~* Positive serology for hepatitis B or C~* History of positive HIV status~* Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment~* Females who are pregnant or breast-feeding~* History of clinically significant drug or alcohol abuse in the last year~* Previous diagnosis or signs of central nervous system demyelinating diseases~* History of tuberculosis, histoplasmosis or listeriosis~* Subjects with latent TB or having other risk factors for activation of latent TB who have not initiated a TB prophylaxis prior to the first adalimumab treatment .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).